Navigation Links
Rigel to Present at the Piper Jaffray Annual Health Care Conference
Date:11/25/2008

SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, Rigel's executive vice president and chief operating officer, will present a company overview at the Twentieth Annual Piper Jaffray Health Care Conference on Wednesday, December 3, 2008 at 3:00 p.m. EST at The New York Palace Hotel in New York City.

To access the live audio webcast or the subsequent archived recording, log on to http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Rigel Announces Third Quarter 2007 Financial Results
2. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
3. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
4. Rigel Announces Offering of 4,000,000 Shares of Common Stock
5. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
6. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
7. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
8. Rigel Announces First Quarter 2008 Financial Results
9. Rigel to Present at Collins Stewart Growth Conference
10. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
11. Rigel to Webcast Investor Update on October 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international ... travel, spa and beauty in Europe. The organization asked its partner experts in Europe ... researchers - to forecast where wellness is headed in Europe. Predictions range from European ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... The Orthopaedic ... executive committee members: , David G. Lewallen, MD, began his term as president ... president. Michael L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will ...
(Date:5/31/2016)... , ... May 31, 2016 , ... In a recent ... Feiner and broadcast on New Rochelle, NY-based WVOX (1460 AM), leading medical ... what she calls the country’s “modern medical money maelstrom.” , During the interview ...
(Date:5/31/2016)... ... May 31, 2016 , ... To meet a growing demand ... industry, The University of Scranton is adding a Certificate in Health Informatics to ... in rapidly growing field of healthcare information. , Healthcare organizations are under ...
(Date:5/30/2016)... , ... May 30, 2016 , ... ... use inside of FCPX," said Christina Austin - CEO of Pixel Film Studios. ... use within Final Cut Pro X. Choose from abstract transitions to more simple ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 2016 RnRMarketResearch.com adds "Asthma - ... analysis of Asthma therapy at various stages, therapeutics assessment ... administration (RoA) and molecule type, along with latest updates, ... key players involved in the therapeutic development for Asthma ... Complete report on H1 2016 pipeline review of ...
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
Breaking Medicine Technology: